{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:44:20Z","timestamp":1793043860024,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01285-x","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T13:29:46Z","timestamp":1745242186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Basophilia and eosinophilia in primary myelofibrosis: phenotype, genotype, and prognostic correlates"],"prefix":"10.1038","volume":"15","author":[{"given":"Sarah","family":"Dingli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9979-7923","authenticated-orcid":false,"given":"Saubia","family":"Fathima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyansh","family":"Faldu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"1285_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"1285_CR2","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/ajh.26821","volume":"98","author":"J Thiele","year":"2023","unstructured":"Thiele J, Kvasnicka HM, Orazi A, Gianelli U, Gangat N, Vannucchi AM, et al. The international consensus classification of myeloid neoplasms and acute leukemias: Myeloproliferative neoplasms. Am J Hematol. 2023;98:544\u20135.","journal-title":"Am J Hematol"},{"key":"1285_CR3","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507\u201313.","journal-title":"Blood"},{"key":"1285_CR4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","volume":"94","author":"N Szuber","year":"2019","unstructured":"Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, et al. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clin Proc. 2019;94:599\u2013610.","journal-title":"Mayo Clin Proc"},{"key":"1285_CR5","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/leu.2010.5","volume":"24","author":"F Girodon","year":"2010","unstructured":"Girodon F, Dutrillaux F, Broseus J, Mounier M, Goussot V, Bardonnaud P, et al. Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients. Leukemia. 2010;24:900\u20133.","journal-title":"Leukemia"},{"key":"1285_CR6","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/ajh.27270","volume":"99","author":"A Tefferi","year":"2024","unstructured":"Tefferi A, Vannucchi AM. Risk models in myelofibrosis-the past, present, and future. Am J Hematol. 2024;99:519\u201322.","journal-title":"Am J Hematol"},{"key":"1285_CR7","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1182\/blood.2019003347","volume":"135","author":"L Ronner","year":"2020","unstructured":"Ronner L, Podoltsev N, Gotlib J, Heaney ML, Kuykendall AT, O\u2019Connell C, et al. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood. 2020;135:1696\u2013703.","journal-title":"Blood"},{"key":"1285_CR8","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/modpathol.2015.100","volume":"28","author":"L Boiocchi","year":"2015","unstructured":"Boiocchi L, Gianelli U, Iurlo A, Fend F, Bonzheim I, Cattaneo D, et al. Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications. Mod Pathol. 2015;28:1448\u201357.","journal-title":"Mod Pathol"},{"key":"1285_CR9","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/bloodadvances.2019000211","volume":"3","author":"A Carobbio","year":"2019","unstructured":"Carobbio A, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019;3:1729\u201337.","journal-title":"Blood Adv"},{"key":"1285_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/ajh.21593","volume":"85","author":"V De Stefano","year":"2010","unstructured":"De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, et al. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol. 2010;85:97\u2013100.","journal-title":"Am J Hematol"},{"key":"1285_CR11","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","volume":"109","author":"R Landolfi","year":"2007","unstructured":"Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109:2446\u201352.","journal-title":"Blood"},{"key":"1285_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.44","volume":"6","author":"D Barraco","year":"2016","unstructured":"Barraco D, Lasho TL, Gangat N, Finke C, Elala YC, Pardanani A, et al. Leukocytosis and presence of CALR mutation is associated with non-hepatosplenic extramedullary hematopoiesis in primary myelofibrosis. Blood Cancer J. 2016;6:e436.","journal-title":"Blood Cancer J"},{"key":"1285_CR13","doi-asserted-by":"publisher","first-page":"E35","DOI":"10.1002\/ajh.26423","volume":"97","author":"F Farrukh","year":"2022","unstructured":"Farrukh F, Guglielmelli P, Loscocco GG, Pardanani A, Hanson CA, De Stefano V, et al. Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. Am J Hematol. 2022;97:E35\u2013E37.","journal-title":"Am J Hematol"},{"key":"1285_CR14","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/ajh.27079","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Loscocco GG, Farrukh F, Szuber N, Mannelli F, Pardanani A, et al. A globally applicable \u201ctriple A\u201d risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count. Am J Hematol. 2023;98:1829\u201337.","journal-title":"Am J Hematol"},{"key":"1285_CR15","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/ajh.27261","volume":"99","author":"I Krecak","year":"2024","unstructured":"Krecak I, Lekovic D, Arsenovic I, Holik H, Zekanovic I, Moric Peric M, et al. The triple A model (age, absolute neutrophil count, absolute lymphocyte count-AAA) predicts survival and thrombosis in polycythemia vera. Am J Hematol. 2024;99:989\u201392.","journal-title":"Am J Hematol"},{"key":"1285_CR16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/bjh.15061","volume":"183","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Shah S, Mudireddy M, Lasho TL, Barraco D, Hanson CA, et al. Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. Br J Haematol. 2018;183:835\u20138.","journal-title":"Br J Haematol"},{"key":"1285_CR17","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.leukres.2006.12.025","volume":"31","author":"MA Elliott","year":"2007","unstructured":"Elliott MA, Verstovsek S, Dingli D, Schwager SM, Mesa RA, Li CY, et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res. 2007;31:1503\u20139.","journal-title":"Leuk Res"},{"key":"1285_CR18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/modpathol.2012.165","volume":"26","author":"L Boiocchi","year":"2013","unstructured":"Boiocchi L, Espinal-Witter R, Geyer JT, Steinhilber J, Bonzheim I, Knowles DM, et al. Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease. Mod Pathol. 2013;26:204\u201312.","journal-title":"Mod Pathol"},{"key":"1285_CR19","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/ajh.24740","volume":"92","author":"D Barraco","year":"2017","unstructured":"Barraco D, Cerquozzi S, Gangat N, Patnaik MM, Lasho T, Finke C, et al. Monocytosis in polycythemia vera: Clinical and molecular correlates. Am J Hematol. 2017;92:640\u20135.","journal-title":"Am J Hematol"},{"key":"1285_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/10245332.2017.1376843","volume":"23","author":"M Lucijanic","year":"2018","unstructured":"Lucijanic M, Livun A, Stoos-Veic T, Pejsa V, Jaksic O, Cicic D, et al. High absolute basophil count is a powerful independent predictor of inferior overall survival in patients with primary myelofibrosis. Hematology. 2018;23:201\u20137.","journal-title":"Hematology"},{"key":"1285_CR21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/ajh.27530","volume":"100","author":"L Yuen","year":"2025","unstructured":"Yuen L, Gogakos T, Boiocchi L, Hobbs G, Hasserjian R. Basophilia Predicts Poorer Outcomes in Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis, and Myeloproliferative Neoplasm, Unclassifiable. Am J Hematol. 2025;100:320\u20132.","journal-title":"Am J Hematol"},{"key":"1285_CR22","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00277-015-2380-5","volume":"94","author":"S Koumas","year":"2015","unstructured":"Koumas S, Prokopiou C, Lerni M, Seimeni O, Neokleous N. Isochromosome 17q10 associated with basophilia in primary myelofibrosis while with JAK2 inhibitor. Ann Hematol. 2015;94:1421\u20132.","journal-title":"Ann Hematol"},{"key":"1285_CR23","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3389\/fonc.2019.00872","volume":"9","author":"J Dobrowolski","year":"2019","unstructured":"Dobrowolski J, Pasca S, Teodorescu P, Selicean C, Rus I, Zdrenghea M, et al. Persistent Basophilia May Suggest an \u201cAccelerated Phase\u201d in the Evolution of CALR-Positive Primary Myelofibrosis Toward Acute Myeloid Leukemia. Front Oncol. 2019;9:872.","journal-title":"Front Oncol"},{"key":"1285_CR24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000527695","volume":"146","author":"A Patel","year":"2023","unstructured":"Patel A, Juskevicius R, Mohan S. Novel JAK2 Exon 14 Mutations L611S or N622Y in cis with JAK2V617F Are Associated with Distinct Clinical Phenotype of Polycythemia Vera and Concurrent Eosinophilia. Acta Haematol. 2023;146:76\u201381.","journal-title":"Acta Haematol"},{"key":"1285_CR25","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1002\/ajh.27007","volume":"98","author":"HM Kantarjian","year":"2023","unstructured":"Kantarjian HM, Tefferi A. Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress. Am J Hematol. 2023;98:1350\u20133.","journal-title":"Am J Hematol"},{"key":"1285_CR26","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118:686\u201392.","journal-title":"Blood"},{"key":"1285_CR27","doi-asserted-by":"crossref","unstructured":"McGowan-Jordan J, Hastings RJ, Moore S: ISCN 2020: An International System for Human Cytogenomic Nomenclature, Basel; Hartford: Karger, [2020], 2020 pp. 503","DOI":"10.1159\/isbn.978-3-318-06867-2"},{"key":"1285_CR28","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29:392\u20137.","journal-title":"J Clin Oncol"},{"key":"1285_CR29","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018;32:1631\u201342.","journal-title":"Leukemia"},{"key":"1285_CR30","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, et al. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. J Clin Oncol. 2018;36:1769\u201370.","journal-title":"J Clin Oncol"},{"key":"1285_CR31","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703\u20138.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01285-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01285-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01285-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T13:29:51Z","timestamp":1745242191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01285-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1285"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01285-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AT and NG are members of the editorial board for BCJ.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of the Mayo Clinic (IRB protocol number: 12-003574). All methods were performed in accordance with the Declaration of Helsinki, the relevant guidelines, and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"72"}}